Japan’s Ministry of health, health and labor has approved a photoimmunotherapy drug for the treatment of head and neck cancer, the first approved photoimmunotherapy drug in the world. Akalux, a new cancer drug developed by Rakuten medical company in Japan, was approved on the 25th for patients with head and neck cancer that cannot be removed by surgery, the Japan Broadcasting Association television reported on the 29th. Akalux contains antibodies that attack cancer cells and chemicals that can react to light. After the drugs combine with cancer cells, they are irradiated with near-infrared laser to activate the antibodies in the drugs, so as to destroy cancer cells. This treatment is called photoimmunotherapy. < p > < p > in addition, according to the daily news, when the drug was used in clinical trials in the United States, patients experienced symptoms such as pain and edema, but there were no serious side effects that were considered to be caused by the drug. < / P > < p > Kobayashi, who works for the National Institutes of health in the United States, worked with Lotte medical in the study. Kobayashi and others held a press conference in Tokyo on the 29th. He said that he was very happy that the drug was approved for use in Japan and hoped that photoimmunotherapy would become a new choice for cancer treatment. Google said the proposed media negotiation rules would put its free services in Australia at “risk”